Microbiome-derived ethanol in nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
To test the hypothesis that the gut microbiota of individuals with nonalcoholic fatty liver disease (NAFLD) produce enough ethanol to be a driving force in the development and progression of this complex disease, we performed one prospective clinical study and one intervention study. Ethanol was measured while fasting and 120 min after a mixed meal test (MMT) in 146 individuals. In a subset of 37 individuals and in an external validation cohort, ethanol was measured in portal vein blood. In an intervention study, ten individuals with NAFLD and ten overweight but otherwise healthy controls were infused with a selective alcohol dehydrogenase (ADH) inhibitor before an MMT. When compared to fasted peripheral blood, median portal vein ethanol concentrations were 187 (interquartile range (IQR), 17-516) times higher and increased with disease progression from 2.1 mM in individuals without steatosis to 8.0 mM in NAFL 21.0 mM in nonalcoholic steatohepatitis. Inhibition of ADH induced a 15-fold (IQR,1.6- to 20-fold) increase in peripheral blood ethanol concentrations in individuals with NAFLD, although this effect was abolished after antibiotic treatment. Specifically, Lactobacillaceae correlated with postprandial peripheral ethanol concentrations (Spearman's rho, 0.42; P < 10-5) in the prospective study. Our data show that the first-pass effect obscures the levels of endogenous ethanol production, suggesting that microbial ethanol could be considered in the pathogenesis of this highly prevalent liver disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548 · cited 1×
“Obtained reads were quality trimmed using Trimmomatic 44 with sliding_window_ threshold_q_score of 15.”
MethodFast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
The SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055
Search and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,826
Naïve Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy
Wang, Q., Garrity, G. M., Tiedje, J. M., & Cole, J. R. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.00062-07 · Cited by 19,885
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“In addition, the Nonalcoholic Fatty Liver Disease Activity Score, which is the sum of the scores for steatosis (range, 0 to 3), bal-looning (range, 0 to 2), and lobular inflammation (range, 0 to 3), with higher scores indicating greater disease activity, was assessed 33 .”
BackgroundNear-optimal probabilistic RNA-seq quantification
Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016) · Nature Biotechnology · doi:10.1038/nbt.3519 · Cited by 9,723
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,414
Cited by
The gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
MAFLD: How is it different from NAFLD?
Gofton, C., Upendran, Y., Zheng, M.-H., & George, J. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0367 · Cited by 423
Fecal microbiota transplantation: current challenges and future landscapes
Yadegar, A., Bar-Yoseph, H., Monaghan, T. M., Pakpour, S., Severino, A., Kuijper, E. J., Smits, W. K., Terveer, E. M., Neupane, S., Nabavi-Rad, A., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-22 · Cited by 351
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Updated mechanisms of MASLD pathogenesis
Li, Y., Yang, P., Ye, J., Xu, Q., Wu, J., & Wang, Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02108-x · Cited by 300
Metadata
- Authors
- Meijnikman, A. S., Davids, M., Herrema, H., Aydin, O., Tremaroli, V., Rios-Morales, M., Levels, H., Bruin, S., de Brauw, M., Verheij, J., Kemper, M., Holleboom, A. G., Tushuizen, M. E., Schwartz, T. W., Nielsen, J., Brandjes, D., Dirinck, E., Weyler, J., Verrijken, A., De Block, C. E. M., Vonghia, L., Francque, S., Beuers, U., Gerdes, V. E. A., Bäckhed, F., Groen, A. K., & Nieuwdorp, M.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Gothenburg (SE)
- Spaarne Ziekenhuis (NL)
- Amsterdam University Medical Centers (NL)
- Leiden University Medical Center (NL)
- University of Copenhagen (DK)
- Chalmers University of Technology (SE)
- Antwerp University Hospital (BE)
- Corresponding author
- Nieuwdorp, Max
- ORCID
- Meijnikman, Abraham S.
- Davids, Mark
- Herrema, Hilde
- Aydin, Omrum
- Tremaroli, Valentina
- Rios-Morales, Melany
- Bruin, Sjoerd
- Verheij, Joanne
- Kemper, Marleen
- Holleboom, Adriaan G.
- Tushuizen, Maarten E.
- Schwartz, Thue W.
- Nielsen, Jens
- Dirinck, Eveline
- Weyler, Jonas
- Verrijken, An
- Vonghia, Luisa
- Francque, Sven
- Beuers, Ulrich
- Gerdes, Victor E. A.
- Bäckhed, Fredrik
- Groen, Albert K.
- Nieuwdorp, Max
- Venue
- Nature Medicine
- Published
- 2022-10
- Volume
- 28
- Issue
- 10
- Pages
- 2100-2106
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4304080702
- Cited by
- 215
- References
- 49
- Citations by year
- 2026: 40 · 2025: 57 · 2024: 56 · 2023: 55 · 2022: 5
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Chalmers Research (Chalmers University of Technology) (submittedVersion)
- Funders
- Eli Lilly and Company
- Gilead Sciences
- Health~Holland
- Amsterdam University Medical Centers (09150182010020)
- European Foundation for the Study of Diabetes
- ZonMw ([09150182010020], 17CVD01, 2019.82.004)
- Diabetes Fonds (2019.82.004)
- Fonds Wetenschappelijk Onderzoek (1802154N)
- Novo Nordisk Fonden (NNF15SA0018346, NNF15OC0016798, 09150182010020)
- Vlaamse regering
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, gut microbiota, endogenous ethanol production, first-pass metabolism, alcohol dehydrogenase inhibition, antibiotic therapy, Lactobacillaceae, disease progression
- MeSH terms
- Alcohol Dehydrogenase, Ethanol, Anti-Bacterial Agents, Humans, Liver, Prospective Studies, Microbiota, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microbiome-derived ethanol in nonalcoholic fatty liver disease. https://app.cochat.ai/papers/10.1038/s41591-022-02016-6
- The paper
- Meijnikman, A. S., Davids, M., Herrema, H., Aydin, O., Tremaroli, V., Rios-Morales, M., Levels, H., Bruin, S., de Brauw, M., Verheij, J., Kemper, M., Holleboom, A. G., Tushuizen, M. E., Schwartz, T. W., Nielsen, J., Brandjes, D., Dirinck, E., Weyler, J., Verrijken, A., . . . Nieuwdorp, M. (2022). Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nature Medicine. https://doi.org/10.1038/s41591-022-02016-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.